Dynamic Technology Lab Private Ltd Purchases 41,132 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• Dynamic Technology Lab Private Ltd has increased its stake in Eyepoint Pharmaceuticals by 127.8%, acquiring an additional 41,132 shares and bringing its total to 73,310 shares.
• Eyepoint Pharmaceuticals experienced a net loss with an EPS of (0.85), missing analyst expectations, and reported revenue of $5.33 million for the last quarter.
• Analysts have generally rated Eyepoint Pharmaceuticals with a "Buy" rating, with a consensus price target of $26.86, slightly below HC Wainwright's target of $23.00.

Dynamic Technology Lab Private Ltd raised its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 127.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,310 shares of the company's stock after acquiring an additional 41,132 shares during the quarter. Dynamic Technology Lab Private Ltd owned approximately 0.11% of Eyepoint Pharmaceuticals worth $397,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Eyepoint Pharmaceuticals by 3,174.4% in the first quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock valued at $56,000 after buying an additional 9,936 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at approximately $76,000. Arizona State Retirement System lifted its stake in Eyepoint Pharmaceuticals by 12.7% in the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after buying an additional 1,877 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at approximately $91,000. Finally, New York State Common Retirement Fund lifted its stake in Eyepoint Pharmaceuticals by 208.8% in the first quarter. New York State Common Retirement Fund now owns 20,114 shares of the company's stock valued at $109,000 after buying an additional 13,600 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company's stock.

Eyepoint Pharmaceuticals Price Performance

NASDAQ:EYPT traded up $0.21 during mid-day trading on Tuesday, reaching $13.62. The stock had a trading volume of 330,683 shares, compared to its average volume of 801,433. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $14.42. The business's 50 day moving average is $11.19 and its 200 day moving average is $8.39. The stock has a market cap of $938.48 million, a P/E ratio of -5.12 and a beta of 1.93.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $6.82 million. Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%. Equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on EYPT shares. Chardan Capital reiterated a "buy" rating and issued a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. HC Wainwright boosted their price objective on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Finally, Royal Bank Of Canada initiated coverage on Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Eyepoint Pharmaceuticals has an average rating of "Buy" and a consensus price target of $26.86.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.